10x Genomics (NASDAQ:TXG) Hits New 52-Week High on Analyst Upgrade

10x Genomics (NASDAQ:TXG) reached a new 52-week high on Tuesday after Piper Sandler raised their price target on the stock from $15.00 to $19.00. Piper Sandler currently has a neutral rating on the stock. 10x Genomics traded as high as $17.28 and last traded at $17.08, with a volume of 5042775 shares changing hands. The stock had previously closed at $15.25.

A number of other analysts have also commented on TXG. Barclays lifted their price target on 10x Genomics from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research upgraded shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday, October 14th. UBS Group raised their target price on 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $14.88.

Insider Activity

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,149 shares of company stock worth $539,865 in the last three months. Company insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of large investors have recently modified their holdings of TXG. ARK Investment Management LLC increased its stake in 10x Genomics by 8.1% during the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock valued at $160,871,000 after purchasing an additional 1,046,390 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of 10x Genomics by 6.7% in the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock valued at $155,177,000 after buying an additional 834,272 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of 10x Genomics by 12.2% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock worth $69,688,000 after acquiring an additional 654,597 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. raised its holdings in shares of 10x Genomics by 12.1% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock worth $69,532,000 after acquiring an additional 646,997 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Trading Up 0.6%

The firm has a market cap of $2.08 billion, a P/E ratio of -26.92 and a beta of 2.13. The company’s 50-day moving average is $13.00 and its two-hundred day moving average is $11.95.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The firm had revenue of $149.00 million during the quarter, compared to analyst estimates of $142.50 million. During the same period in the previous year, the company posted ($0.30) EPS. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. 10x Genomics has set its Q4 2025 guidance at EPS. Research analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.